Clinical Trials Logo

Autistic Disorder clinical trials

View clinical trials related to Autistic Disorder.

Filter by:

NCT ID: NCT02668991 Completed - Clinical trials for Autism Spectrum Disorder

Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort

Start date: July 2015
Phase: Phase 0
Study type: Observational

The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.

NCT ID: NCT02654743 Completed - Autism Clinical Trials

Open Label of Clinical Trial of Sulforaphane in Children With Autism

Start date: January 2016
Phase: Phase 3
Study type: Interventional

This is an open-label, 4-month study examining the effects of Sulforaphane (SF) on behavior in children with ASD and the correlation between behavior change and urinary metabolites. The goal is to determine a potential mechanism of action of SF in this population.

NCT ID: NCT02649959 Active, not recruiting - Autism Clinical Trials

An Open Label Study of CM-AT for the Treatment of Children With Autism

Start date: October 2015
Phase: Phase 3
Study type: Interventional

This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.

NCT ID: NCT02646696 Completed - Clinical trials for Autism Spectrum Disorder

Reliability Study Using Electrodermal Activity to Measure Sensory Processing in Children With and Without Autism Spectrum Disorder

Start date: January 2013
Phase: N/A
Study type: Observational

The purpose of this study is tTho establish test-retest reliability of electrodermal markers used to quantify physiologic response to sensation using the Sensory Challenge Protocol in children with and without Autism Spectrum Disorder (ASD).

NCT ID: NCT02632773 Completed - Autism Clinical Trials

Parent Language Intervention for Autism

Start date: August 2015
Phase: N/A
Study type: Interventional

Improving social communication outcomes for children with autism spectrum disorders (ASD) has important public health implications. The proposed research is a randomized controlled trial of 108 children with ASD that examines how specific parent characteristics influence outcomes of two different parent-mediated language interventions. Evaluating effective language intervention strategies for children with ASD supports NIDCD's mission of behavioral research aimed to remediate the disordered process of language development in children with ASD.

NCT ID: NCT02628808 Recruiting - Clinical trials for Autism Spectrum Disorders

Susceptibility Genes in Autism Spectrum Disorders

Start date: August 2008
Phase: N/A
Study type: Observational

The main objective of the study is to define, for Autism Spectrum Disorder, the extent of genetic variation in synaptic pathways that may be targeted for therapeutic development. For this purpose the investigators will take advantage of large, well-characterized cohorts of patients with Autism Spectrum Disorder for genetic screenings. Targeted sequencing of selected synaptic genes, previously associated with Autism Spectrum Disorder, will be carried out in these cohorts with deep coverage of coding regions and a strong focus on previously untested regulatory regions. Genomic data from Copy Number Variant, whole genome sequencing and exome sequencing, available for some of these patients, will be integrated in the overall analysis. The investigators will strongly emphasize the establishment of comprehensive genotype/phenotype correlations and set up an induced Pluripotent Stem Cells collection from selected patients with synaptic mutations for functional and expression analysis.

NCT ID: NCT02627508 Recruiting - Clinical trials for Autism Spectrum Disorder

Pilot Trial of Pregnenolone in Autism

Start date: January 29, 2016
Phase: Phase 2
Study type: Interventional

This is a research study to examine the tolerability and effectiveness of pregnenolone in individuals with autism. Pregnenolone is a naturally occurring steroid hormone in the brain that has been implicated in treating various psychiatric conditions. The investigators hope to learn the effects and safety of using pregnenolone in reducing irritability and sensitivity to sensory differences and improving social communication in individuals with autism. The investigators hope by studying the effects of pregnenolone in more detail, the investigators can design better ways to treat individuals with autism.

NCT ID: NCT02627131 Completed - Autistic Disorder Clinical Trials

Autologous Bone Marrow Stem Cell Therapy for Autism

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism.

NCT ID: NCT02625116 Active, not recruiting - Clinical trials for Autism Spectrum Disorders

ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders

ELENA
Start date: September 27, 2014
Phase:
Study type: Observational

The objective of the ELENA French Cohort is to study the developmental trajectories of children and adolescents with ASD and their risk or protective associated factors. This is an open, prospective and multicenter cohort study, including children and adolescents under 16 years of age with ASD recruited from services specialized in the assessment of developmental disorders.

NCT ID: NCT02617342 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Robot-Mediated Intervention for Children With Autism Spectrum Disorders

Start date: November 2015
Phase: N/A
Study type: Interventional

This study is being done to examine the impact of an interactive, social robotics program in helping children with autism spectrum disorders (ASD) understand emotions and how to better recognize emotions while interacting with others. Eligible families will be randomized to either the robot intervention (n=20) or a no intervention (TAU; n=20) condition for 8-14 weeks. Assessments will occur at pre- and post-intervention as well as weekly for both conditions.